安水 洋太

Medicine & Life Sciences

1. Prostatic Neoplasms 100%
2. Renal Cell Carcinoma 76%
3. Castration 68%
4. Prostatectomy 54%
5. Docetaxel 41%
6. Recurrence 32%
7. Prostate-Specific Antigen 27%
8. Triple Negative Breast Neoplasms 26%
9. Carcinoma 26%
10. Neoplasms 25%
11. Prostatic Hyperplasia 24%
12. Urinary Bladder Neoplasms 22%
13. Therapeutics 20%
14. Survival 20%
15. Chromatin Assembly and Disassembly 19%
16. Neoplasm Metastasis 19%
17. Mucin-1 18%
18. Phosphatidylinositol 3-Kinases 18%
19. Neoplastic Stem Cells 17%
20. Androgens 16%
21. Progression-Free Survival 16%
22. Prostate 15%
23. dactolisib 14%
24. Salvage Therapy 14%
25. Radiotherapy 14%
26. Drug Therapy 13%
27. Paclitaxel 13%
28. Thymidylate Synthase 12%
29. Mi-2 Nucleosome Remodeling and Deacetylase Complex 12%
30. Lymphocele 12%
31. Clear-cell metastatic renal cell carcinoma 11%
32. Dutasteride 11%
33. cabazitaxel 11%
34. pazopanib 11%
35. Prenatal Ultrasonography 10%
36. Lymph Node Excision 10%
37. Cisplatin 10%
38. (arginine)9-cysteinyl-glutaminyl-cysteinyl-arginyl-arginyl-lysyl-asparagine 10%
39. Multiparametric Magnetic Resonance Imaging 10%
40. Volatilization 10%
41. Neutrophils 9%
42. Multivariate Analysis 9%
43. Single Photon Emission Computed Tomography Computed Tomography 9%
44. Pyruvate Kinase 9%
45. Neoadjuvant Therapy 9%
46. Semiconductor Lasers 9%
47. Pharmaceutical Services 9%
48. Febrile Neutropenia 9%
49. Down-Regulation 8%
50. Seminal Vesicles 8%